TriangleHEALTH PROFESSIONAL · SOURCE READING
Trastuzumab Deruxtecan (T-DXd)
Source: Agnostic Cancer Therapies (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: HER2–Expressing Solid Tumors
Indication. T-DXd is indicated for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.[1] This indication is not approved in the pediatric population.
Source links and citations
Evidence. One hundred ninety-two adult patients with previously treated unresectable or metastatic HER2-positive (IHC 3+) solid tumors were enrolled in one of the following three multicenter trials:[2-4][Level of evidence C3]
Source links and citations
DESTINY-PanTumor02 (NCT04482309).[2]
Source links and citations
DESTINY-Lung01 (NCT03505710).[3]
Source links and citations
DESTINY-CRC02 (NCT04744831).[4]
Source links and citations
Efficacy. The objective response rates were as follows:
51.4% (95% confidence interval [CI], 41.7%–61.0%) for patients in the DESTINY-PanTumor02 trial.
52.9% (95% CI, 27.8%–77.0%) for patients in the DESTINY-Lung01 trial.
46.9% (95% CI, 34.3%–59.8%) for patients in the DESTINY-CRC02 trial.
Identification of biomarker. Eligible patients had centrally confirmed HER2 positivity (IHC 3+).
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice